CG Oncology names Isabel Kalofonos chief commercial officer
CGON•CG Oncology named Isabel Kalofonos chief commercial officer as it prepares for a potential launch of cretostimogene grenadenorepvec.
1. Commercial leadership appointment
Kalofonos previously served as chief commercial officer at Crinetics Pharmaceuticals, supporting the launch of PALSONIFY before its sale to Vertex. She also led the launch of ELAHERE at ImmunoGen and held senior commercial roles at Galderma, Takeda and Shire.
